Response to "Do We Need On‐Site Drug Analysis Within Supervised Injecting Facilities?".

The article discusses the importance of on-site drug analysis at Medically Supervised Injecting Centres (MSIC) in enhancing safety and risk management for individuals using illicit substances. It responds to arguments against such testing, emphasizing that while MSIC has a commendable safety record, the increasing contamination of the drug supply necessitates proactive measures to further reduce risks associated with drug use. The authors argue that on-site drug testing can provide critical information for clinical responses to adverse events, countering the notion that post-event toxicological assessments are sufficient. They highlight the need for individualized, substance-based approaches to managing overdose risks, particularly with potent opioids. Overall, the article advocates for integrating on-site drug analysis as a valuable tool in harm reduction strategies. [Extracted from the article]